INT50070

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1993
Last Reported 2009
Negated 2
Speculated 0
Reported most in Abstract
Documents 14
Total Number 16
Disease Relevance 3.76
Pain Relevance 5.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
capillary 1
striatum 1
brain 1
cortex 1
Body 1
NFKBIL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
analgesia 7 100.00 Very High Very High Very High
fortral 14 99.98 Very High Very High Very High
opioid receptor 20 99.96 Very High Very High Very High
Opioid 12 99.96 Very High Very High Very High
agonist 18 99.68 Very High Very High Very High
adenocard 5 98.98 Very High Very High Very High
Thalamus 4 97.64 Very High Very High Very High
Hippocampus 4 96.60 Very High Very High Very High
cva 3 95.24 Very High Very High Very High
aspirin 4 93.76 High High
Disease Link Frequency Relevance Heat
Obesity 16 100.00 Very High Very High Very High
Body Weight 2 99.90 Very High Very High Very High
Disease 11 99.82 Very High Very High Very High
Cv General 3 Under Development 3 95.24 Very High Very High Very High
INFLAMMATION 2 92.00 High High
Adhesions 1 90.68 High High
Infection 4 88.64 High High
Miosis 2 86.56 High High
Hematuria 1 82.64 Quite High
Pressure And Volume Under Development 3 82.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For a surrogate to authorize removal of LST from a patient in a nonterminal condition, there must be compelling evidence indicative of the patient's wishes.
Negative_regulation (removal) of LST
1) Confidence 0.48 Published 2004 Journal Crit Care Section Body Doc Link PMC420027 Disease Relevance 0 Pain Relevance 0
Society may not impose objective QoL assessments to facilitate removal of LST from individuals perceived as unworthy or useless without risking the welfare of entire populations of disabled or otherwise disenfranchized citizens.
Negative_regulation (removal) of LST
2) Confidence 0.36 Published 2004 Journal Crit Care Section Body Doc Link PMC420027 Disease Relevance 0 Pain Relevance 0
This conflict forces several issues: what level of evidence is required to justify removal of LST, which standard of surrogacy should be applied, and how ought QoL and the preservation of life be balanced?
Negative_regulation (removal) of LST
3) Confidence 0.36 Published 2004 Journal Crit Care Section Body Doc Link PMC420027 Disease Relevance 0 Pain Relevance 0
This inhibition prevented the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B was retained in the cytosol.
Negative_regulation (inhibitor) of I kappa B
4) Confidence 0.16 Published 1994 Journal Science Section Abstract Doc Link 8052854 Disease Relevance 0.36 Pain Relevance 0.27
Thus, differential blockade of mu-like and kappa-like opioid effects by naltrexone was demonstrated in human subjects.
Negative_regulation (blockade) of kappa-like associated with opioid
5) Confidence 0.08 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7679737 Disease Relevance 0.32 Pain Relevance 0.84
Immunofluorescence studies revealed intensive deposition of IgG, IgA, C3, C1q, Fibrinogen, and kappa light chain with granular pattern in the capillary and mesangial area.
Negative_regulation (deposition) of kappa light chain in capillary
6) Confidence 0.07 Published 2009 Journal Clin. Exp. Nephrol. Section Abstract Doc Link 19367362 Disease Relevance 0.78 Pain Relevance 0.27
Indeed, its potential inhibitory effect through the stimulation of mu receptors (normally prevented by the concomitant stimulation of kappa 1 receptors) becomes efficient only when kappa 1 receptors are blocked.
Negative_regulation (blocked) of kappa 1
7) Confidence 0.02 Published 1994 Journal Neuropeptides Section Abstract Doc Link 7969822 Disease Relevance 0 Pain Relevance 1.00
However, the hippocampus had high levels of kappa 1-inhibited adenylyl cyclase despite low levels of kappa 1 binding, while cortex exhibited a high density of kappa 1 sites but a relatively low level of kappa 1-inhibited adenylyl cyclase.
Negative_regulation (level) of kappa 1-inhibited in cortex associated with hippocampus
8) Confidence 0.01 Published 1993 Journal Biochem. Pharmacol. Section Abstract Doc Link 8381004 Disease Relevance 0 Pain Relevance 0.33
Comparison between kappa 1 binding and kappa 1-inhibited adenylyl cyclase across eleven guinea pig brain regions revealed that kappa 1-inhibited adenylyl cyclase was highest in the cerebellum, absent in thalamus and superior colliculus, and moderate in other regions.
Negative_regulation (inhibited) of kappa 1-inhibited in cerebellum associated with thalamus
9) Confidence 0.01 Published 1993 Journal Biochem. Pharmacol. Section Abstract Doc Link 8381004 Disease Relevance 0 Pain Relevance 0.28
Reaction of cerebellar kappa receptors with beta-chlornaltrexamine (beta-CNA) blocked both kappa 1 binding and kappa 1-inhibited adenylyl cyclase.
Negative_regulation (blocked) of kappa 1
10) Confidence 0.01 Published 1993 Journal Biochem. Pharmacol. Section Abstract Doc Link 8381004 Disease Relevance 0 Pain Relevance 0.32
The present studies explore the relationship between kappa 1 binding sites (as determined with [3H]U-69,593 binding) and kappa 1-inhibition of adenylyl cyclase (using U-50,488H) in guinea pig brain membranes.
Negative_regulation (inhibition) of kappa 1 in brain
11) Confidence 0.01 Published 1993 Journal Biochem. Pharmacol. Section Abstract Doc Link 8381004 Disease Relevance 0 Pain Relevance 0.21
The results indicate that a marked loss of adenosine A1 receptors occurs in the striatum of AD with no loss of kappa 1 opioid receptors, and that the loss of A1 receptors parallels the loss of choline acetyltransferase activity.
Neg (no) Negative_regulation (loss) of kappa 1 in striatum associated with adenocard, opioid receptor and disease
12) Confidence 0.01 Published 1993 Journal Brain Res. Section Abstract Doc Link 8395303 Disease Relevance 0.69 Pain Relevance 0.25
The mu, delta, and kappa 1 analgesia is unaffected by this antisense treatment.
Neg (unaffected) Negative_regulation (unaffected) of kappa 1 associated with analgesia
13) Confidence 0.01 Published 1995 Journal Mol. Pharmacol. Section Abstract Doc Link 7603458 Disease Relevance 0 Pain Relevance 0.37
Given supraspinally, the sigma1receptor agonist (+)pentazocine diminished systemic mu, delta, kappa1, and kappa3 opioid analgesia in CD-1 mice.
Negative_regulation (diminished) of kappa1 associated with fortral, agonist, opioid and analgesia
14) Confidence 0.01 Published 2002 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11861817 Disease Relevance 0 Pain Relevance 1.12
At room temperature mu1, mu2 and delta opioid receptor binding was reduced between 6 and 12 hours, whereas kappa1 and kappa3 binding was reduced after 24 hours.
Negative_regulation (reduced) of kappa1 associated with opioid receptor
15) Confidence 0.01 Published 1997 Journal Life Sci. Section Abstract Doc Link 9366506 Disease Relevance 0 Pain Relevance 0.24
Body weight was reduced following chronic mu (lean: 42 g; obese: 49 g), mu1 (lean: 71 g; obese: 38 g), kappa1 (lean: 30 g; obese 14 g), delta1 (lean: 43 g; obese: 22 g) or delta2 (lean: 37.5 g; obese: 36 g) antagonism.
Negative_regulation (reduced) of kappa1 in Body associated with body weight and obesity
16) Confidence 0.00 Published 1997 Journal Peptides Section Abstract Doc Link 9396062 Disease Relevance 1.62 Pain Relevance 0.41

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox